19 April 2022 - Nuvaxovid is the first protein-based COVID-19 vaccine approved for use in adults aged 18 and older in Japan.
Novavax today announced that its partner Takeda received manufacturing and marketing approval from the Japan Ministry of Health, Labour and Welfare for its Nuvaxovid intramuscular injection, Novavax' novel recombinant protein-based COVID-19 vaccine, for primary and booster immunisation in individuals aged 18 and older.